BIOCON.NS : Summary for BIOCON INR5 - Yahoo Finance

U.S. Markets closed

Biocon Limited (BIOCON.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
1,103.70-16.90 (-1.51%)
At close: 3:29PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1,120.60
Bid1,103.70 x
Ask0.00 x
Day's Range1,082.60 - 1,125.00
52 Week Range583.40 - 1,188.00
Avg. Volume588,860
Market Cap216.27B
PE Ratio (TTM)19.03
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 days ago

    India watchdog orders antitrust probe into Roche cancer drug

    India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.

  • Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
    Zacks2 months ago

    Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

    Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

  • PR Newswire2 months ago

    U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

    HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta®  (pegfilgrastim), for filing through the 351(k) pathway.